Natco End Period Cash Flow from 2010 to 2024

NATCOPHARM   1,415  39.60  2.88%   
Natco Pharma's End Period Cash Flow is increasing with slightly volatile movements from year to year. End Period Cash Flow is estimated to finish at about 10 B this year. For the period between 2010 and 2024, Natco Pharma, End Period Cash Flow quarterly trend regression had median of  258,000,000 and r-value of  0.63. View All Fundamentals
 
End Period Cash Flow  
First Reported
2004-12-31
Previous Quarter
7.2 B
Current Value
8.1 B
Quarterly Volatility
1.5 B
 
Housing Crash
 
Credit Downgrade
 
Yuan Drop
 
Covid
Check Natco Pharma financial statements over time to gain insight into future company performance. You can evaluate financial statements to find patterns among Natco Pharma's main balance sheet or income statement drivers, such as Depreciation And Amortization of 2 B, Interest Expense of 180 M or Total Revenue of 42 B, as well as many indicators such as . Natco financial statements analysis is a perfect complement when working with Natco Pharma Valuation or Volatility modules.
  
This module can also supplement various Natco Pharma Technical models . Check out the analysis of Natco Pharma Correlation against competitors.

Also Currently Popular

Analyzing currently trending equities could be an opportunity to develop a better portfolio based on different market momentums that they can trigger. Utilizing the top trending stocks is also useful when creating a market-neutral strategy or pair trading technique involving a short or a long position in a currently trending equity.

Other Information on Investing in Natco Stock

Natco Pharma financial ratios help investors to determine whether Natco Stock is cheap or expensive when compared to a particular measure, such as profits or enterprise value. In other words, they help investors to determine the cost of investment in Natco with respect to the benefits of owning Natco Pharma security.